A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-30. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Feature films === Phang's debut feature film that she directed and wrote was entitled Half-Life (2008) and it starred Sanoe Lake, Julia Nickson-Soul, Leonardo Nam, James Eckhouse, Susan Ruttan and Alexander Agate. The film premiered at the 2008 Sundance Film Festival in the New Frontiers section, and also screened at the Gen Art Film Festival (where it won a Best Feature award), the San Francisco International Asian American Film Festival (where it won a Best Narrative award), the Asian American International Film Festival (where Phang won the "Emerging Director Award"), the Fairy Tales International Gay & Lesbian Film Festival (where it won the Visionary Award), the Tokyo International Film Festival (where it was in-competition and was nominated for the Tokyo Grand Prix), the Mannheim-Heidelberg International Film Festival (where it was also in competition and nominated for the Main Award), and the International Women's Film Festival in Seoul, Korea (where it was opening night film). The film received a limited theatrical release on December 1, 2009. After Half life, Phang's follow-up project was, Look For Water, and Crazy Beats Strong Every Time. Phang received a grant from the Sundance Institute Cinereach Grant, the Sundance Annenberg Feature Film Fellowship, and the Tribeca Film Festival to support these developments. Phang's follow up film that she directed, wrote and edited was Advantageous (2015), which was based on her award-winning short film of the same name. The film starred Jacqueline Kim, Ken Jeong, James Urbaniak, Freya Adams and Samantha Kim.
FIAU is then phosphorylated stepwise: thymidine kinase (TK) converts FIAU to FIAU-monophosphate (FIAU-MP), then thymidylate kinase (TMPK) forms FIAU-diphosphate (FIAU-DP) and finally nucleoside-diphosphate kinase (DPK) produces FIAU-triphosphate (FIAU-TP). FIAU-TP can be incorporated into viral or cellular DNA (figure 4). In addition, thymidylate synthase (TS) has the potential to de-iodinate FIAU to FAU and then subsequently methylate FAU to FMAU monophosphate. FMAU monophosphate can subsequently be converted into FMAU diphosphate by thymidine monophosphate kinase (TMPK). Finally, FMAU diphosphate can be converted into FMAU triphosphate by the enzyme diphosphate kinase (DPK) with the purpose of incorporation into the viral or cellular DNA. FIAU does not exist as only one compound inside the cell, its metabolites can also contribute and FAU can ultimately be incorporated as FMAU in whole cells.
Additionally, a new research program called ACTINET has been started in the EU to make transmutation possible on an industrial scale. According to U. S. President Bush's Global Nuclear Energy Partnership (GNEP) of 2007, the United States is actively promoting research on transmutation technologies needed to markedly reduce the problem of nuclear waste treatment. There have also been theoretical studies involving the use of fusion reactors as so-called "actinide burners" where a fusion reactor plasma such as in a tokamak, could be "doped" with a small amount of the "minor" transuranic atoms which would be transmuted (meaning fissioned in the actinide case) to lighter elements upon their successive bombardment by the very high energy neutrons produced by the fusion of deuterium and tritium in the reactor. A study at MIT found that only two or three fusion reactors with parameters similar to that of the International Thermonuclear Experimental Reactor (ITER) could transmute the entire annual minor actinide production from all of the light-water reactors presently operating in the United States fleet while simultaneously generating approximately one gigawatt of power from each reactor. Opportunities for managing nuclear waste by transmutation are also being explored in linear particle accelerators.
== Subfamily B2 == Subfamily B2 (also known as the adhesion G protein-coupled receptor family) contains receptors with long extracellular N-termini, such as the leukocyte cell-surface antigen CD97; calcium-independent receptors for latrotoxin and brain-specific angiogenesis inhibitor receptors amongst others. However, in some more recent classifications, they are no longer considered part of the same family as secretin (due to significant differences, like autocatalytic processing and different cell functions).
Sources: en.wikipedia.org
Vitamin E is fat soluble, so dietary supplement products are usually in the form of the vitamin, esterified with acetic acid to generate tocopheryl acetate, and dissolved in vegetable oil in a softgel capsule. For alpha-tocopherol, amounts range from 100 to 1000 IU per serving. Smaller amounts are incorporated into multi-vitamin/mineral tablets. Gamma-tocopherol and tocotrienol supplements are also available from dietary supplement companies. The latter are extracts from palm oil.
Charles Jerrard. For services to the British Limbless Ex-Service Men's Association in Romford, Essex. Andy Derrick Johnson, Section Leader, Mathematics and Technology Department, Southwark College, London. For services to Education. George Refoy Johnston, Vice Chairman, Eildon Housing Association. For services to Housing. Samuel Hans Johnston, Process and General Supervisory Grade D, Ministry of Defence. Carol Theresa Jones, lately Senior Personal Secretary, the Highways Agency, Department of Transport. David Charles Newhams Jones, lately Journalist, Ashton Reporter. For services to Journalism in Lancashire. David Lloyd Jones, lately Chief Executive, Arfon Borough Council. For services to Local Government. Howard Leslie Jones, Maintenance Technician, Stanlow Manufacturing Complex, Shell UK Ltd. For services to Health and Safety. Ivy Jones. For services to the community in Tayside. Janice Jones. For services to the community, particularly Young Children, in Adamsdown, Cardiff. Robert Meinon Jones. For services to Choral Music in the District of Ffestiniog, Gwynedd. Lieutenant Colonel Robert Ian Hywel-Jones, , Senior Executive Officer, Foreign and Commonwealth Office. Trevor Mostyn Jones. For services to the Environment in North East England. Vera Daisy Jones. For political and public service. Wendy Keene. For political service. Eileen Grace Kelly. For services to the community in Pulborough, West Sussex. Donald Fraser Kennedy, Honorary Chairman, Dalneigh Senior Citizen's Club. For services to Elderly People in Inverness. Richard Leighton Keys.
Larger doses do not appear to increase risks in this population. A broader retrospective study found that the rate of hyperkalemia in gender-diverse individuals is correlated with age, with those above 45 years old being more at risk. The finding suggests that patients below or at 45 years old without other conditions that affect potassium handling can be spared from routine monitoring.
Sources: en.wikipedia.org
Firearms is a first-person shooter mod for Half-Life which originated from a Quake modification. Initially developed in 1998, Firearms was created as a quasi-realistic team-based FPS. The mod's main feature is the large amount of usable weapons in the game.
=== Signs and symptoms === Death caps have been reported to taste pleasant. This, coupled with the delay in the appearance of symptoms—during which time internal organs are being severely, sometimes irreparably, damaged—makes them particularly dangerous. Initially, symptoms are gastrointestinal in nature and include colicky abdominal pain, with watery diarrhea, nausea, and vomiting, which may lead to dehydration if left untreated, and, in severe cases, hypotension, tachycardia, hypoglycemia, and acid–base disturbances. These first symptoms resolve two to three days after the ingestion. A more serious deterioration signifying liver involvement may then occur—jaundice, diarrhea, delirium, seizures, and coma due to fulminant liver failure and attendant hepatic encephalopathy caused by the accumulation of normally liver-removed substances in the blood. Kidney failure (either secondary to severe hepatitis or caused by direct toxic kidney damage) and coagulopathy may appear during this stage. Life-threatening complications include increased intracranial pressure, intracranial bleeding, pancreatic inflammation, acute kidney failure, and cardiac arrest. Death generally occurs six to sixteen days after the poisoning. It is noticed that after up to 24 hours have passed, the symptoms seem to disappear and the person might feel fine for up to 72 hours. Symptoms of liver and kidney damage start 3 to 6 days after the mushrooms were eaten, with the considerable increase of the transaminases. Mushroom poisoning is more common in Europe than in North America.
Counter-Strike was the most successful, having been released in six different editions: as a standalone product (2000), as part of the Platinum Pack (2000), as an Xbox version (2003), and as a single-player spin-off, Counter-Strike: Condition Zero (2004), as well as in two versions using the Source engine. Team Fortress Classic, Day of Defeat, Gunman Chronicles (2000, a futuristic Western movie-style total conversion with emphasis on its single-player mode) and Sven Co-op were also released as standalone products. Half-Life is also the subject of the YouTube improv roleplaying series Half-Life VR but the AI is Self-Aware and Freeman's Mind. In 2003, Valve's network was infiltrated by hackers. Among the stolen files was the unreleased Half-Life mod Half-Life: Threewave, a canceled remake of the Quake mod Threewave CTF. The files were found by fans on a Vietnamese FTP server in February 2016 and unofficially distributed that September.
== Function == Gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid polypeptide synthesized by K cells of the duodenum and small intestine. It was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release potently in the presence of elevated glucose. The insulinotropic effect on pancreatic islet beta-cells was then recognized to be the principal physiologic action of GIP. Together with glucagon-like peptide-1, GIP is largely responsible for the secretion of insulin after eating. It is involved in several other facets of the anabolic response.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.